EXHIBIT 10.1
LICENSE AGREEMENT
This License (this "Agreement"), effective October 17, 2000, is
between Lactoferrin Products Company ("Lactoferrin"), Mannatech Incorporated
("Mannatech"), and Marcus B. Gohlke ("Gohlke"). All three parties agree as
follows.
1. GENERAL DEFINITIONS
1.1 Advance Payment: The "Advance Payment" is defined in Section
5.1.1.
1.2 BE Agreement: The "BE Agreement" means the July 22, 2000
agreement between Lactoferrin Products Company and Biopolymer Engineering, Inc.
attached as EXHIBIT B.
1.3 Book: The "Book" means the book entitled "Immune System Control"
by Beth M. Ley PhD.
1.4 Contract Year: The twelve months beginning on the first day of
the calendar month of the Effective Date is the first Contract Year. Successive
Contract Years follow accordingly.
1.5 Dietary Supplement: "Dietary Supplement" means a dietary
supplement as understood in the United States and as may be understood or
requested in other countries as a food, drug, etc.
1.6 Effective Date: The "Effective Date" is identified in the first
paragraph of this Agreement.
1.7 Glucan Improvement: The "Glucan Improvement" is defined in
Section 8.2.
1.8 Improvements: "Improvements" means improvements, developments,
and modifications to the inventions of the Licensed Patents or to any part of
the Licensed Technology, Licensed Business Information, whether or not
patentable, made, conceived or acquired during the Term by either party or to
which either party obtains rights which it can provide to the other without
obligation to third parties, including changes made for the purpose of improving
the operation, efficiency or manufacturability of the Licensed Product or
processes relating thereto.
1.9 Licensed Business Information: The "Licensed Business
Information" means Lactoferrin trade secrets related to business relationships
with raw material suppliers, manufacturers and distributors concerning the
manufacture or sale of the Licensed Product.
1.10 Licensed Patents: "Licensed Patents" means: (1) the patents
licensed under the BE Agreement; (2) any patents that issue from US patent
application 09/370,654, filed 08/06/99 or Canadian patent application 2,279,791,
filed 08/06/99; and (3) any other patents that, during the term
1
of this Agreement, Lactoferrin can sublicense to Mannatech that cover the
Licensed Product or any process relating to the manufacture or use of the
Licensed Product.
1.11 Licensed Product: A "Licensed Product" means a solid dietary
supplement (1) having the formulation identified in EXHIBIT A, or (2) otherwise
covered by a Licensed Patent, or (3) made using the Licensed Technology provided
by Lactoferrin for the Licensed Products of clause (1) or (2).
1.12 Licensed Technology: The "Licensed Technology" means
formulations, designs, drawings, diagrams, photographs, graphs, charts,
calculations, specifications, manuals, reports, and other data, know-how and
experience describing the configuration, manufacture, testing, maintenance and
use of the Licensed Product (clause (1) or (2) of the definition of "License
Product"), whether patented or held as trade secret that Lactoferrin has the
right during the term of this Agreement to disclose to Mannatech.
1.13 Minimum Royalty: The "Minimum Royalty" is defined in Section
5.1.3.
1.14 Parties: The "parties" and a "party" means Lactoferrin and
Mannatech, and excludes Gohlke, unless otherwise expressly indicated.
1.15 Per Unit Royalty: The "Per Unit Royalty" is defined in Section
5.1.2.
1.16 Raw Material: The "Raw Material" is colostrum powder and beta
1,3/1,6 glucan.
1.17 Royalty Due: The "Royalty Due" is defined in Section 5.1.
1.18 Royalty Unit: A "Royalty Unit" is an amount of Licensed Product
equal to a one month supply based on the daily suggested use or an equivalent
amount. An example of a Royalty Unit is a sixty (60) count bottle or blister
pack where two (2) counts are suggested for daily use.
2. LICENSE GRANTS
2.1 Licensed Products: Subject to the terms of this Agreement,
Lactoferrin grants to Mannatech an exclusive, worldwide license (with no right
to sublicense) to make, have made, use, sell, offer, import, and export Licensed
Products under (1) the Licensed Patents, (2) the Licensed Technology, and (3)
Lactoferrin's rights under the BE Agreement. Mannatech acknowledges that
exclusivity under the BE Agreement requires certain conditions be met.
Lactoferrin and Mannatech shall execute the sublicense required by the BE
Agreement, but nothing in that sublicense shall expand or modify Mannatech's
rights as granted under this Agreement. Subject to the terms of this Agreement,
Lactoferrin grants to Mannatech an exclusive, worldwide license to use the
Licensed Business Information to make and sell the Licensed Product. Lactoferrin
shall not assert any Licensed Patent against any activities permitted by the
licenses granted in this section.
2
2.2 Advertising Materials: Conditioned upon Lactoferrin's prior
written approval of any use (which approval shall not be unreasonably withheld
or delayed), Lactoferrin grants to Mannatech an exclusive, worldwide license to
reproduce, prepare derivative works, distribute, perform and display: (1)
Lactoferrin's written and video advertising materials for the Licensed Product;
and (2) Lactoferrin's audio scripts related to colostrum/lactoferrin product and
synergy with Ambrotose(R).
2.3 Asia Exception: Notwithstanding any provision of this Agreement,
Lactoferrin may continue its sales of dietary supplements (a combination of
colostrum and lactoferrin and not containing beta glucan) to Genesis Trading
Limited of Hong Kong and Grand Stone Corporation of Orange County, California
for resale in Asia but not in Japan, and except that the dietary supplements may
not be sold for resale to a multi-level marketer. However, one year after the
earlier of: (1) written notice by Mannatech of its intent to enter the Asia
market with the Licensed Product or (2) Mannatech's notice of actual entry in
the Asia market with the Licensed Product, Lactoferrin shall cease selling into
Asia the dietary supplement (a combination of colostrum and lactoferrin)
currently sold in Asia. No sales of its dietary supplements (a combination of
colostrum and lactoferrin) may be made by Lactoferrin in Japan or for ultimate
delivery or sale to Japan.
2.4 Retained Rights: Lactoferrin retains all rights necessary to
make, have made, use, sell, offer for sale, import and export, worldwide,
dietary supplements, whether solid, liquid or any form, (A) comprising no more
two of the following: (1) colostrum; (2) lactoferrin; (3) modified citrus
pectin; and (4) beta glucan, but (B) not including the combination of colostrum
and lactoferrin or the combination of colostrum and beta 1,3/1,6 glucan.
2.5 License Limitations
2.5.1 Prohibited Countries: The licenses granted in this
Agreement shall not include any country where such grants, or exportation of the
Licensed Technology, is prohibited by US law or the law of such country.
2.5.2 Prior Agreements: All licenses are subject to any prior
agreements between Lactoferrin and others entered before the Effective Date.
Lactoferrin represents it has disclosed all such agreements and that none would
materially affect the value of this Agreement or rights conferred hereunder.
3. MANNATECH OBLIGATIONS
3.1 Best Efforts to Market: Mannatech shall use its reasonable best
efforts to market Licensed Product.
3.2 Formula Requirement: Mannatech may use any of the four
ingredients set forth in EXHIBIT A to make, have made, use, sell, offer, import,
and export Licensed Product. Any
3
departures from the ranges of ingredients set forth in EXHIBIT A must be
approved in writing by Lactoferrin.
3.3 Use Prohibitions: Mannatech shall not use the Licensed
Technology, the Licensed Business Information, or the advertising materials
except as expressly permitted in this Agreement.
3.4 Trademarks: Mannatech shall mark or label the Licensed Product
with the trademark "Beta Right" for any Licensed Product manufactured with beta
1,3/1,6 glucan from Biopolymer Engineering Incorporated as indicated in EXHIBIT
B. Mannatech shall mark or label the Licensed Product with the trademark "Prime
Colostrum" for any Licensed Product manufactured with colostrum from Immuno-
Dynamics, Inc. Nothing herein shall grant any right to Mannatech to use any
Lactoferrin trademark or tradename, and Mannatech shall not use any Lactoferrin
trademark or tradename.
3.5 Patent Notice: Mannatech shall mark all Licensed Product
packaging and advertising comprising beta 1,3/1,6 glucan:
"Protected by US patents 5,576,015; 5,519,009; 5,397,773; 5,705,184;
and 5,702,719. Other US and Canadian patents pending."
("the Glucan Patents") or otherwise as Lactoferrin may direct by written notice.
Mannatech shall mark all Licensed Product packaging and advertising not
comprising beta 1,3/1,6 glucan:
"US and Canadian patents pending."
or otherwise as Lactoferrin may direct by written notice. In making such notice,
Mannatech relies upon representations of Lactoferrin that the beta 1,3/1,6
glucan used in the Dietary Supplements is covered by the Glucan Patents. If
Lactoferrin becomes aware that a product marketed by Mannatech containing
colostrum and lactoferrin does not fall within the scope of any Licensed Patent,
Lactoferrin will provide notice to Mannatech.
3.6 Packaging of the Licensed Product: Mannatech may package the
Licensed Product in any package, size or quantity at Mannatech's option.
3.7 Confidentiality: Except as expressly permitted, Mannatech shall
not use or disclose, or permit others to use or disclose any Improvements,
Licensed Technology, or Licensed Business Information, and shall protect all
such information in confidence. Mannatech shall disclose Improvements, Licensed
Technology, or Licensed Business Information only to employees, vendors and
manufacturers who have a need to know. Mannatech shall have no obligation to
maintain as confidential information which is in or becomes in the public domain
or becomes known to the public through no fault of Mannatech. The obligations of
this section shall survive after the termination of this Agreement.
4
3.8 Sublicenses: Mannatech shall not sublicense any rights granted
under this Agreement without the express written consent of Lactoferrin.
3.9 Raw Material Purchase: Mannatech shall purchase Raw Material
from raw material suppliers identified in Paragraph 4.2 of this Agreement.
4. LACTOFERRIN OBLIGATIONS
4.1 Disclosures: Lactoferrin, through Marcus B. Gohlke, shall make
the Licensed Technology and Licensed Business Information available to Mannatech
commencing on the Effective Date of this Agreement. Upon reasonable request with
advance notice by Mannatech, Marcus B. Gohlke shall make himself available to
make the disclosure and cooperate with Mannatech in connection with the
development of its products. If Mannatech requests with advance notice for
Marcus B. Gohlke to travel to a location more than fifty (50) miles from Marcus
B. Gohlke's residence, Mannatech shall pay all reasonable, requested travel,
meals and lodging expenses. Lactoferrin shall authorize and instruct
Lactoferrin's patent counsel to provide to Mannatech's patent counsel a copy of
US patent application 09/370,654, filed 08/06/99 or Canadian patent application
2,279,791, filed 08/06/99 within a reasonable time from the effective date of
this Agreement.
4.2 Raw Materials
4.2.1 Colostrum Powder: Lactoferrin shall deliver to Mannatech
colostrum powder at Lactoferrin's cost, not to exceed $120 per kilogram for the
first three Contract Years. The parties may negotiate a different, lower price
based on the volume of colostrum powder purchased. Lactoferrin will use Immuno-
Dynamics, Inc., having a place of business at Intersection Highway 141 and 169,
Perry, Iowa, as a source for the colostrum powder. Based on present knowledge,
Lactoferrin represents $120 per kilogram is the lowest cost negotiated for
colostrum power from Immuno-Dynamics, Inc.
4.2.2 Glucan: Lactoferrin shall deliver to Mannatech beta
1,3/1,6 glucan at Lactoferrin's cost not to exceed $500 per kilogram according
to the terms of the BE Agreement. Lactoferrin will use Biopolymer Engineering
Incorporated, having a place of business at 445 Etna Street, Suite 58, St. Paul,
Minnesota as a source for the beta 1,3/1,6 glucan. Based on present knowledge,
Lactoferrin represents $500 per kilogram is the lowest cost negotiated for beta
1,3/1,6 glucan from Biopolymer Engineering Incorporated. Mannatech acknowledges
that Lactoferrin has entered into the BE Agreement. Mannatech agrees to execute
the Sublicense Agreement (Attachment A) of the BE Agreement. Lactoferrin shall
provide confirmation of Biopolymer Engineering Incorporated's approval of
Mannatech as sublicensee.
4.2.3 Orders and Supply: Mannatech shall pay for the Raw
Materials FOB the raw material supplier and shall pay Lactoferrin 30 days net.
If Mannatech is current on all payments
5
due under this Agreement, Lactoferrin will accept purchase orders from Mannatech
for Raw Material.
4.2.4 Substitutions: Lactoferrin shall make no substitutions
in the suppliers of the Raw Materials unless agreed in writing by Lactoferrin
and Mannatech. If either of the raw material suppliers noted in paragraphs
4.2.1 and 4.2.2 fail to supply satisfactory Raw Material and Lactoferrin cannot
substitute a reasonable raw material supplier within 30 days with goods
substantially similar to those provided pursuant to paragraphs 4.2.1 and 4.2.2,
Mannatech may terminate this Agreement upon notice as provided in paragraphs
10.4 and 11.6.
4.3 The Book: Upon request by Mannatech, and to the extent
Lactoferrin can purchase copies of the Book, Lactoferrin shall sell copies of
the Book to Mannatech upon payment by Mannatech of $2.95 per copy, plus shipping
and handling.
5. ROYALTIES AND PAYMENTS
5.1 Product Royalty: The Licensed Product Royalty shall be
calculated and paid on a monthly basis for receipt by Lactoferrin on or before
the last day of each month. The Royalty Due means the greater of (1) the Per
Unit Royalty or (2) the Minimum Royalty, as the case may be. Whenever a Contract
Years Minimum Royalty has been paid, there will be no further Minimum Royalty
for that year. After the Minimum Royalty has been paid for such Contract Year,
Mannatech shall only pay for sale of any Licensed Product or Products as per the
terms above and at the rate of the Per Unit Royalty below.
5.1.1 Advance Payments: Mannatech shall pay Advance Payments
against Royalty to Lactoferrin in the amount of $72,000 as follows:
$36,000 On the Effective Date
$36,000 90 days after the Effective Date
5.1.2 Per Unit Royalty: The Per Unit Royalty means the royalty
for the Royalty Units of Licensed Product shipped by Mannatech each month:
Number Royalty Units Royalty
-------------------- -------
1 - 540,000 $1.00 per Royalty Unit
540,001 - 1,540,000 $0.90 per Royalty Unit
over 1,540,000 $0.80 per Royalty Unit
5.1.3 Minimum Royalty: The Minimum Royalty shall be calculated
as follows:
Contract Year 1 $12,000 per month less one-twelfth of the advance
royalty but in any event not less than
$6,000/month. Contract Year 1 Minimum Royalty shall
be deemed paid in full when $144,000 total royalty
for the contract year has been paid.
6
Contract Year 2 The greater of $8,000/month or (an amount equal to
a Per Unit Royalty for 110% of the average monthly
number of Royalty Units shipped in Year 1)/month.
Contract Year 2 Minimum Royalty shall be deemed
paid in full when $96,000 total royalty for the
contract year has been paid.
Contract Year 3 (an amount equal to a Per Unit Royalty for 110% of
the average monthly number of Royalty Units shipped
in Year 2)/month or annually as the case may be.
Any Renewal Year (an amount equal to a Per Unit Royalty for 5,000
Royalty Units shipped)/month.
Upon renewal for any renewal year, the parties may negotiate a different Minimum
Royalty not less than an amount equal to a Per Unit Royalty for 5,000 Royalty
Units shipped in a month.
5.2 Advertising Royalty: Mannatech shall pay to Lactoferrin
Advertising Royalties as follows:
5.2.1 For written advertising materials: The parties shall
agree upon a payment for advertising materials shipped
by Mannatech and developed in conjunction with
Lactoferrin, provided that all property and copyright
rights to such works shall belong to Mannatech, solely.
Anything developed by or for Mannatech, independent of
Lactoferrin, concerning the Licensed Product will not
require a payment. Listing the Licensed Product in the
Mannatech products catalog will not require a payment.
5.2.2 For audios and videos: For audios and videos and any
written scripts for audios or videos, developed by
Lactoferrin or jointly by Mannatech and Lactoferrin and
shipped by Mannatech, Mannatech shall pay Lactoferrin 5%
of the total sales price of the item when the same is
shipped.
On or before the last day of each month, Mannatech shall pay and deliver to
Lactoferrin the Advertising Royalty due for the preceding month.
5.3 Payment Procedures: All payments under this Agreement shall be
made in United States currency. Late payments shall bear interest at the lesser
of 10% per annum or the maximum legal rate.
7
5.4 Taxes and Similar Charges: Mannatech shall pay all taxes,
customs duties, import and export fees, currency conversion charges, and other
charges that may be required to enable Mannatech to comply with any and all
government regulations regarding the performance of this Agreement.
5.5 Royalty Calculations: All royalties shall be calculated on the
gross number of items shipped. A Royalty Unit shall be considered shipped when
Mannatech ships to a customer of Mannatech the Royalty Unit. Returns for which a
customer is given credit or reimbursement, and complementary/promotional
products shall be subtracted from the number of products shipped for purposes of
calculating the Product Royalty. For any Licensed Product not covered by any of
the patents licensed under the BE Agreement (by itself or by method of
manufacture), the Per Unit Royalty shall be reduced by 10%. If no patent issues
from US patent application 09/370,654, filed 08/06/99 or Canadian patent
application 2,279,791, filed 08/06/99, or a continuation application of
either, the Per Unit Royalty shall be reduced by 10%.
6. REPORTS, RECORDS, AUDITS
6.1 Written Reports: On or before the last day of the month,
Mannatech shall submit to Lactoferrin a written report showing all royalty
payments paid or otherwise due from Mannatech for the previous month, and the
detailed calculation of each. Without limitation, the report shall include for
the month:
6.1.1 A check with remittance advice showing as to each
product: the number of units shipped, the Minimum
Monthly Royalty, the Product Royalty, the Excess
Royalty, the actual royalty paid, the standing
inventory, the shrinkage (including promotional items)
and returns for credit to customers.
6.1.2 For items governed by paragraph 5.3, a check with
remittance advice reflecting as to each such item:
number of units shipped, Advertising Royalty, actual
royalty paid, standing inventory, shrinkage (including
promotional items) and returns for credit to customers;
and
6.1.3 Any deficiency, and any interest due.
Mannatech's issuance of a signed check with remittance advice shall be
considered a representation by Mannatech that the information in the remittance
advice is true, correct, and prepared in accordance with generally accepted
accounting principles consistently applied from applicable period to period.
6.2 Records: Mannatech shall keep accurate written records (as well
as invoices and shipping and payment records) sufficient to show Mannatech's
performance of all obligations under this Agreement in accordance with generally
accepted accounting principles. Mannatech shall record all sales of the Licensed
Product, by product. Mannatech shall keep all such records regarding Licensed
Product for five years after the end of the Contract Year pertaining to the
records.
8
6.3 Audit: Upon five days written notice, Mannatech shall permit
Lactoferrin or its designee to audit, inspect and copy the books and records of
Mannatech with respect to Licensed Product, including but not limited to
shipments, promotions, and returns of Licensed Product. Mannatech shall
cooperate with Lactoferrin or its designee in providing Lactoferrin reasonable
access to Mannatech's books and records during normal business hours for this
purpose. If Mannatech withholds any records, Mannatech shall pay all of
Lactoferrin's court costs, legal fees, and related costs to obtain Mannatech's
compliance with this section. If the results of any inspection or audit shows
that Mannatech owed five percent 5% or more than actually paid, then Mannatech
shall immediately pay (1) the amounts shown due (including interest) and (2) all
reasonable out of pocket costs and expenses of the audit. If the results of any
inspection or audit shows that Mannatech owed less than five percent 5% of the
amount actually paid, then Mannatech shall immediately pay (1) the amounts shown
due (including interest) and Lactoferrin shall pay all reasonable out of pocket
costs and expenses of the audit. Lactoferrin shall only audit the records after
Contract Year 1 of this Agreement and shall perform audits in a manner
calculated not to disrupt the ongoing business of Mannatech.
7. PATENT ENFORCEMENT AND INFRINGEMENT
7.1 Claims against third parties: If Mannatech believes that any
person is infringing a Licensed Patent, Mannatech shall provide written notice
to Lactoferrin that shall include evidence of the infringement. If Lactoferrin
files suit against the person of the accused activity, then:
7.1.1 If required by law, Mannatech will join as a nominal
plaintiff and Mannatech shall cooperate as a witness to
assist in the prosecution of Lactoferrin's claims if
requested by Lactoferrin, and Mannatech may at its own
discretion and expense be represented by independent
counsel;
7.1.2 Lactoferrin shall bear all expenses of the suit, except
expenses related to independent counsel of Mannatech;
and
7.1.3 Lactoferrin shall retain all recoveries (by judgment,
settlement, or otherwise).
If Lactoferrin does not file suit against the person of the accused activity
within six (6) months after Mannatech's notice, then Mannatech may but shall not
have the obligation to file suit against the accused infringer, and:
7.1.4 If required by law, Lactoferrin will join as a nominal
plaintiff and Lactoferrin shall cooperate as a witness
to assist in the prosecution of Mannatech's claims if
requested by Mannatech, and Lactoferrin may at its own
discretion and expense be represented by independent
counsel, and Lactoferrin will assign its rights and
interests in its claims to Mannatech;
7.1.5 Mannatech shall bear all expenses of the suit, except
expenses related to independent counsel of Lactoferrin;
and
7.1.6 Mannatech shall retain all recoveries (by judgment,
settlement, or otherwise).
9
Nothing herein shall prevent the Parties from entering into an agreement to
jointly file suit, jointly bear the expenses and jointly retain recoveries,
should they so agree in writing in the future. Nothing herein shall require
Lactoferrin or Mannatech to file or prosecute any actions for infringement.
7.2 Claims by Third Parties: If the use of Licensed Patents,
Licensed Technology, or Licensed Products results in a claim for infringement
against Mannatech, Mannatech shall pay its own expenses for defense and damages,
unless the same be in reliance on any representation in paragraph 9.2.7.
7.3 Notice of Third Party Claims: Mannatech shall provide Gohlke and
Lactoferrin prompt notice of and reasonable opportunity to participate in the
defense of any action against Mannatech relating to the licensing, sale or other
disposition of Licensed Product, Licensed Technology, or Licensed Products.
Lactoferrin and Gohlke shall have no obligation to participate in any such
defense.
8. IMPROVEMENTS
8.1 Improvements: Inventions or Improvements conceived or reduced to
practice solely by a party during the term of and in connection with this
Agreement shall be owned exclusively by such party.
8.2 Glucan Improvement: The "Glucan Improvement" means a dietary
supplement containing: (1) colostrum; (2) lactoferrin; (3) modified citrus
pectin; and (4) beta 1,3/1,6 glucan. The parties acknowledge that the Glucan
Improvement is an Improvement under this Agreement and that the Glucan
Improvement is owned by Mannatech.
8.3 Improvement Patents: Each Party, at its own discretion, may
prepare, file and prosecute patent applications on its own behalf in the United
States and foreign countries for Improvements. Each Party shall bear all costs
and fees associated with any application filed by the party.
9. REPRESENTATIONS AND INDEMNITIES
9.1 Rights in Licensed Technology: Lactoferrin hereby represents and
warrants only that it is the exclusive licensing agent for the Licensed
Technology. Relative to the patents licensed under the BE Agreement, Lactoferrin
hereby represents of its current actual knowledge and gives warranty limited by
its current actual knowledge that it is the exclusive licensee of Biopolymer
Engineering, Inc. for dietary and nutritional supplements incorporating beta
1,3/1,6 glucan, and/or beta 1,3 glucan, and/or derivative(s) of these glucans
and using an oral cavity delivery system (for example, chewables) or
formulation, excluding capsules, tablets or any system which delivers outside
the oral cavity according to the terms of the BE agreement and as confirmed by
the Acknowledgment by Biopolymer Engineering, Inc. attached as EXHIBIT C.
Relative to Licensed Business Information, Licensed Technology and any patents
that issue from US patent application
10
09/370,654, filed 08/06/99 or Canadian patent application 2,279,791, filed
08/06/99, Lactoferrin hereby represents of its current actual knowledge and
warrants that it is the owner of the rights to the technology according to
assignments from the inventors wherein a copy of the assignment is attached as
EXHIBIT D. Lactoferrin makes no other representation, guarantee or warranty,
including without limitation the completeness, validity, accuracy or
noninfringing character of the Licensed Technology furnished under this
Agreement; and no such warranty or guarantee shall be implied by interpretation
of any term of this Agreement or by any course of dealing between the parties
hereto. Lactoferrin's obligations with respect to the Licensed Technology are
strictly limited to any Warranty provision herein, and Mannatech agrees to
always act in accordance therewith. Lactoferrin makes no other representation or
warranty respecting the technical information furnished under this Agreement.
9.2 Representations by Lactoferrin and Gohlke: Lactoferrin and
Gohlke represent of their current actual knowledge:
9.2.1 the Licensed Product is an exclusive formulation, not
previously produced, marketed or sold;
9.2.2 there are no similar products derived from the
formulation of the Licensed Product;
9.2.3 that Gohlke, his partners or business associates, and/or
Lactoferrin have US patent application 09/370,654, filed
08/06/99 and Canadian patent application 2,279,791,
filed 08/06/99 pending for a dietary supplement
containing lactoferrin, colostrum and modified citrus
pectin, and he/they reasonably believe such patents will
be granted, and further that the USPTO has issued a
first office action in which the examiner indicated
that no prior art was found which anticipates the
invention as claimed in many of the claims filed in US
patent application 09/370,654;
9.2.4 there are no legal actions or proceedings pending
against Lactoferrin or Gohlke;
9.2.5 that no prior art exists which is a basis for a court to
render any Licensed Patent invalid;
9.2.6 that no prior art exists which is a basis for a court to
render any Licensed Patent unenforceable;
9.2.7 that no patents of third parties exist which would be
infringed by the Licensed Technology or any Licensed
Product.
9.3 Representations by Lactoferrin: Lactoferrin represents of its
current actual knowledge:
9.3.1 Lactoferrin is a corporation duly organized and in good
standing under the laws of its state of incorporation;
11
9.3.2 all necessary business governance issues have been
authorized to enter the agreement;
9.3.3 no other consent is required to enter the agreement;
9.3.4 Lactoferrin has other agreements with third parties
which have been disclosed to Mannatech, but entering
this Agreement will not cause Lactoferrin to breach any
other agreement of which it is a party pertaining to the
subject matter of this Agreement;
9.3.5 all taxes are current;
9.3.6 the relationship between Lactoferrin and its suppliers
and customers is generally good; and
9.3.7 Lactoferrin is solvent.
9.4 Representations by Mannatech: Mannatech represents of its
current actual knowledge:
9.4.1 Mannatech is solvent;
9.4.2 No other consent is required to enter the agreement,
other than the Board of Directors;
9.4.3 Mannatech is not in bankruptcy;
9.4.4 Mannatech is not aware that it is in material breach of
any other agreement which with notice and opportunity to
cure would render an adverse effect on this Agreement;
9.4.5 Mannatech is a corporation duly organized and in good
standing under the laws of its state of incorporation;
9.5 Exclusion of Warranties: Lactoferrin makes no other
representation concerning the Licensed Product, the Licensed Patents, the
Licensed Technology, or the Licensed Business Information. Mannatech waives any
claim against Lactoferrin for any failure of the Licensed Product, the Licensed
Patents, the Licensed Technology, the Licensed Business Information, or parts,
components or ingredients thereof to perform fully. LACTOFERRIN EXCLUDES ANY
WARRANTY: (1) AS TO THE VALIDITY, ENFORCEABILITY, OR SCOPE OF ANY LICENSED
PATENT; AND (2) AS TO THE COMPLETENESS OR ACCURACY OF THE VALIDITY,
ENFORCEABILITY, OR NONINFRINGING CHARACTER OF THE LICENSED PATENTS AND THE
LICENSED TECHNOLOGY. NO SUCH WARRANTIES SHALL BE IMPLIED BY INTERPRETATION OF
ANY TERM OR BY ANY COURSE OF DEALING, EXCEPT AS PROVIDED HEREIN.
9.6 Notice Concerning Patent: Lactoferrin shall provide notice to
Mannatech, if Lactoferrin comes to know or be aware that:
9.6.1 prior art exists which is a basis for a court to render
any Licensed Patent invalid;
9.6.2 prior art or evidence exists which is a basis for a
court to render any Licensed Patent unenforceable;
12
9.6.3 any Licensed Product infringes a patent of a third
party, and
9.6.4 any Licensed Product is outside the scope of all
Licensed Patents.
Any failure of Lactoferrin to provide notice under this paragraph shall not
affect Mannatech's obligations under this Agreement except to the extent of any
claim by Mannatech for actual damages.
9.7 Indemnity by Mannatech: Mannatech shall indemnify, defend, and
hold Lactoferrin and Gohlke harmless from any damages (including consequential
and special damages), expenses, and costs (including reasonable attorneys' fees)
relating to intentional acts or gross negligence of Mannatech, a Mannatech
employee, or an officer of Mannatech, acting within the course of business of
Mannatech and, if an officer, within the scope of such officer's authority.
9.8 Indemnitees' Obligations: Gohlke and/or Lactoferrin shall
promptly notify Mannatech of any claim or action subject to indemnity. Gohlke
and/or Lactoferrin shall provide Mannatech complete information and cooperation
in the defense or settlement of the claim and shall not settle or pay any claim
without Mannatech's prior written approval. Failure to perform any obligation in
this section shall not affect Mannatech's indemnity obligations except to the
extent of any claim by Mannatech for actual damages.
9.9 Insurance: Mannatech shall maintain product liability insurance
in the United States and Canada during the term of this Agreement.
10. TERM, TERMINATION AND EXPIRATION
10.1 Term: The term of this Agreement shall be the Initial Term, and
any Renewal Term, unless earlier noticed for termination. The Initial Term
begins on the Effective Date and continues to the end of the Third Contract
Year. All Renewal Terms shall have a duration of three (3) years (the first
Renewal Term shall continue to the end of the Sixth Contract Year, the second
Renewal Term shall continue to the end of the Ninth Contract Year, the third
Renewal Term shall continue to the end of the Twelfth Contract Year, etc.). This
Agreement shall automatically renew for a Renewal Term at the end of any term,
unless Mannatech provides to Lactoferrin written notice under paragraph 10.2
10.2 Termination by Mannatech: Provided Mannatech is not in breach of
this Agreement, Mannatech may terminate this Agreement by written notice to
Lactoferrin at least sixty days before the then-scheduled end of a term (but no
more than 120 days before that date).
10.3 Immediate Termination by Lactoferrin: Lactoferrin may terminate
this Agreement by written notice to Mannatech after notice and 60 days
opportunity to cure:
10.3.1 If Mannatech modifies or alters the formula of a
Licensed Product beyond the ranges
13
provided in EXHIBIT A without Lactoferrin's written
consent;
10.3.2 If Mannatech purchases or obtains Raw Materials from a
source without Lactoferrin's written consent;
10.3.3 If Mannatech dissolves, ceases active business
operations, liquidates substantially all of its assets;
or becomes insolvent;
10.3.4 If Mannatech becomes bankrupt; or
10.3.5 If Lactoferrin is sued by a third party for patent
infringement for Lactoferrin's activities under this
Agreement.
10.4 Immediate Termination by Mannatech: Mannatech may terminate this
Agreement by written notice to Lactoferrin after notice and 60 days opportunity
to cure:
10.4.1 If Lactoferrin supplies Raw Materials from a source
other than those identified in paragraphs 4.2.1 and
4.2.2 without Mannatech's written consent.
10.4.2 If Mannatech has a good faith opinion upon written
advice of patent counsel that Mannatech's activities
under this Agreement constitutes patent infringement of
a third party patent.
10.5 Termination by Law: This agreement shall terminate if it becomes
illegal in the United States to sell or offer for sale Dietary Supplements
containing any of the following ingredients: beta glucan, colostrum, or
lactoferrin.
10.6 Termination Procedures: Upon any termination of this Agreement,
Mannatech shall immediately cease all use of the Licensed Technology, the
Licensed Patents, and the Improvements and shall immediately return or deliver
to Lactoferrin all documents containing any information relating thereto.
10.7 Survival: Sections 3.7 and 9.7, any amounts accrued and owing,
and any claims for breach shall survive expiration or termination of this
Agreement.
11. GENERAL PROVISIONS
11.1 Assignment by Mannatech: The rights and licenses granted by
Lactoferrin in this Agreement are personal to Mannatech and may not be assigned
or otherwise transferred without the
14
written consent of Lactoferrin. Any attempted assignment or transfer without
such consent shall be void and shall automatically terminate all rights and
licenses of Mannatech under this Agreement.
11.2 Assignment by Lactoferrin: The licenses granted in this
Agreement shall be binding upon any successor of Lactoferrin in ownership or
control of the Licensed Technology, and the obligations of Mannatech, including
but not limited to the obligation to make reports and pay royalties, shall run
in favor of any such successor and of any assignee of Lactoferrin's benefits
under this Agreement. Any Assignment by Lactoferrin shall also be binding upon
Marcus B. Gohlke.
11.3 Force Majeure: None of the three parties shall be liable for
failure to perform any obligation when occasioned by contingencies beyond its
control, such as strikes or other work stoppages, lock outs, riots, wars, delay
of carriers, etc., and acts of God, such as fire, floods, storms, earthquakes,
and acts or failures to act of government or governmental agencies or
instrumentalities. A party shall notify the other parties immediately should any
such contingency occur. No party shall be excused from its obligations for a
period of longer than 30 days, without written approval of the other party.
11.4 Choice of Law: This Agreement and the relationship between all
three parties shall be governed in all respects by the laws of the State of
Texas, except that questions affecting the construction and effect of any patent
shall be determined by the law of the country in which the patent has been
granted.
11.5 Severability: If it shall at any time appear that any right or
obligation provided by this Agreement is contrary to any law, treaty, or
regulation, such right or obligation shall be deemed annulled, or shall be
modified to the extent required to comply with such law, treaty or regulation,
unless Lactoferrin, in its sole discretion, objects to the annulment or
modification of any such right or obligation, in which event the Agreement will
be terminable forthwith by Lactoferrin, except as provided in paragraph 10.5
hereof.
11.6 Notice. Any notice given by either party to the other party
shall be in the English language and shall be sent by courier, mail, electronic
mail or electronic transmission (facsimile) confirmed by certified mail to the
other party's signatory at the address set forth below, or to such other address
as a party may indicate by notice in accordance with this section. Notices shall
be deemed delivered on confirmed receipt.
If to Mannatech: Mannatech Incorporated
600 S. Royal Lane, Suite 200
Coppell, Texas 75019
Attn: Terry Persinger with confirmation to Deanne Varner
Phone: 972 471 7387
Fax: 972-471-7264
Email: tpersinger@mail.mannatech-inc.com
15
If to Lactoferrin: Lactoferrin Products Company
12302 Astoria Boulevard
Houston, Texas
Attn: Marcus B. Gohlke
Phone: 281 464 0709
Fax: 281 464 0805
Email: altmed@altmedinfo.com
If to Gohlke: Marcus B. Gohlke
12302 Astoria Boulevard
Houston, Texas
Phone: 281 464 9716
Fax: 281 464 0805
Email: mbg@altmedinfo.com
11.7 Governing Law. This Agreement shall be governed by and construed
in accordance with the laws of the state of Texas, United States of America, as
applicable to contracts made and to be performed within such state without
giving effect to its conflict of law provisions, and all disputes had by one
party against the other shall be brought in a court of competent jurisdiction in
Harris County, State of Texas.
11.8 Entire Agreement: This Agreement contains the entire and only
Agreement between the three parties and supersedes all preexisting Agreements
between them respecting its subject matter. Any representation, promise, or
condition in connection with such subject matter which is not incorporated in
this Agreement shall not be binding upon either party. No modification, renewal,
extension, waiver, and (except as may be provided herein) no termination of this
Agreement or any of its provisions shall be binding upon the party against whom
enforcement of such modification, renewal, extension, waiver, or termination is
sought, unless made in writing and signed on behalf of such party by one of its
executive officers. As used herein, the word "termination" includes any and all
means of bringing to an end prior to its expiration by its own terms this
Agreement, or any provision thereof, whether by release, discharge, abandonment,
or otherwise.
MANNATECH INCORPORATED
/s/ Terry Persinger
-----------------------------------
Name: Terry Persinger
Title: President and Chief Operating Officer Domestic
Date: 10/12/00
------------------------------
16
LACTOFERRIN PRODUCTS COMPANY
/s/ MARCUS B. GOHLKE
----------------------------------- -----------------------------------
Name: Marcus B. Gohlke Name: Richard H. Cockrum
Title: President Title: Member of Board of Directors
Date: 10/4/2000 Date:
------------------------------ ------------------------------
/s/ MARCUS B. GOHLKE
-----------------------------------
Name: Marcus B. Gohlke, individually
Date: 10/4/2000
------------------------------
17
EXHIBIT A - FORMULATION
Formulation for a chewable wherein the suggested use is two chewables per day:
Component Amount
- --------- ------
Prime Colostrum(R) 125.0 - 250.0 mg.
BetaRight(R) Beta 1,3/1,6 Glucan 20.0 - 75.0 mg.
Lactoferrin 10.0 - 25.0 mg.
Modified Citrus Pectin 5.0 - 15.0 mg.
18
EXHIBIT B - BE Agreement
19
LICENSE AGREEMENT
THIS LICENSE AGREEMENT is made and is effective as of the 22/nd/ day of
July, 2000 by and between Biopolymer Engineering, Inc. and its parent, related
or affiliated corporations (together called "BEI") of 445 Etna Street, Suite
58, St. Paul, Minnesota 55106 USA, and Lactoferrin Products Company and its
parent, related or affiliated corporations (together called "Lactoferrin") of
12302 Astoria Boulevard, Houston, TX 77089.
WHEREAS, BEI is a manufacturer and distributor of beta 1,3/1,6 glucan
and/or beta 1,3 glucan.
WHEREAS, Lactoferrin is a manufacturer and distributor of nutritional and
dietary supplements which use an oral cavity delivery system (for example,
lozenges) or formulation, excluding capsules, tablets or any system which
delivers outside the oral cavity.
WHEREAS, the Parties wish to manufacture and distribute a nutritional and
dietary supplement comprising beta 1,3/1,6 glucan and/or beta 1,3 glucan which
uses an oral cavity delivery system or formulation.
NOW WITNESS THEREFORE that in consideration of the premises and the
provisions, stipulations and matters herein set out, the Parties hereto hereby
agree as follows:
1. Definitions: When used in this Agreement, the terms set forth below shall
have the meanings indicated:
EFFECTIVE DATE of this Agreement shall be the date first above
indicated.
IMPROVEMENTS shall mean improvements to the formulation or method of
making the LICENSED PRODUCT within the LICENSED FIELD.
LICENSED FIELD shall mean the field of dietary and nutritional
supplements incorporating beta 1,3/1,6 glucan, and/or beta 1,3 and/or
derivative(s) of these glucans
1
and using an oral cavity delivery system (for example, lozenges) or formulation,
excluding capsules, tablets or any system which delivers outside the oral
cavity.
LICENSED PRODUCT means any and all products that employ, are produced
by the practice of, or used in accordance with inventions claimed in the
LICENSED PATENTS or other patents related to the LICENSED FIELD.
LICENSED PATENTS shall means United States Patents issued numbers:
5,576,015; 5,519,009; 5,397,773; 5,705,184; and 5,702,719 and patents which
relate to inventions in or applicable to the LICENSED PRODUCT and which are
owned or controlled by BEI during the term of this Agreement, or in respect to
which BEI has or may acquire during the term of this Agreement the right to
grant licenses of the scope to be granted in this Agreement.
TRADEMARK shall mean the term "Beta Right" and any rights established
by United States trademark application Serial Number 75/912,109.
2. Technology License: BEI grants to Lactoferrin an exclusive license to make,
have made, use, sell, offer for sale, and import the LICENSED PRODUCT embodying,
made, or used in accordance with the LICENSED PATENTS for use in the LICENSED
FIELD. In addition to all third parties, this license is exclusive of BEI.
3. Technology Use: For all products which Lactoferrin shall make, have made,
use, sell, offer for sale, and import under the license of Paragraph 2, the
products shall contain an effective amount of beta 1,3/1,6 glucan, and/or beta
1,3 glucan, and/or derivative(s) of these glucans, wherein an "effective amount"
is defined as a recommended dose of 40 mg/day.
4. Trademark License: BEI grants to Lactoferrin a nonexclusive license to use
the TRADEMARK in association with LICENSED PRODUCT in the LICENSED FIELD.
2
5. Trademark Use and Control: Lactoferrin shall use the TRADEMARK on all
packaging and labels associated with products containing beta 1,3/1,6 glucan
and/or beta 1,3 glucan purchased from BEI. Approximately once every six months
and at BEI's written request, Lactoferrin shall provide a sample of LICENSED
PRODUCT to BEI.
6. Supply: BEI agrees to supply to Lactoferrin beta 1,3/1,6 glucan and/or beta
1,3 glucan at a rate of five hundred dollars per kilogram ($500.00/kg) or less.
BEI agrees that it shall not supply beta 1,3/1,6 glucan and/or beta 1,3 glucan
to any third party at a rate which is lower than the rate paid by Lactoferrin
for the same product, unless such lower rate is also offered to Lactoferrin for
such product.
7. Purchase: Lactorferrin shall purchase beta 1,3/1,6 glucan and/or beta 1,3
glucan exclusively from BEI.
8. Initial Purchase: Lactoferrin shall purchase five kilograms (5 kg) of beta
1,3/1,6 glucan and/or beta 1,3 glucan from BEI at a price of five hundred
dollars per kilogram ($500.00/kg) on or before the effective date of this
Agreement.
9. Minimum Purchase: This Agreement shall remain in effect for so long as
Lactoferrin purchases quantities of beta 1,3/1,6 glucan and/or beta 1,3 glucan
from BEI according to the following schedule:
year 2000 25 kilogram minimum purchase
year 2001 125 kilogram minimum purchase
year 2002 250 kilogram minimum purchase
For year 2003 and beyond, Lactoferrin must purchase 250 kilograms of beta
1,3/1,6 glucan and/or beta 1,3 glucan per year to keep this Agreement effective.
If Lactoferrin fails to purchase the required quantity of beta 1,3/1,6 glucan
and/or beta 1,3 glucan, as required by this Paragraph 5, this Agreement shall
terminate with no obligations imposed on either Party.
3
10. Marketing: BEI shall direct marketing and publicity efforts to geographic
regions in which Lactoferrin sells and/or promotes LICENSED PRODUCT. BEI shall
feature LICENSED PRODUCT as part of its exclusive sponsorship of the Debra Ray &
Dr. Carrow nationally syndicated health radio talk show "Here's To Your Health".
11. Distribution: Lactoferrin shall be responsible for all sales, marketing,
advertising and distribution of LICENSED PRODUCT into its network of retailers
that currently carry the Alt Med brand as well as other markets that may become
available.
12. Sublicense: Lactoferrin shall have the right to sublicense all rights
granted under this Agreement, qualified only in that Lactoferrin shall require
each sublicensee to execute Sublicense Agreement as attached hereto in
Attachment A. Upon execution by each sublicensee, Lactoferrin shall provide a
copy of the executed Sublicense Agreement to BEI.
13. Patent Enforcement: While and as long as its license under this Agreement
remains exclusive, Lactoferrin is empowered:
(a) to bring suit in its own name or, if required by law, jointly with
BEI, at its own expense and on its own behalf, for infringement of the LICENSED
PATENTS in the LICENSED FIELD;
(b) in any such suit, to enjoin infringement and to collect for its use,
damages, profits, and awards of whatever nature recoverable for such
infringement; and
(c) to settle any claim or suit for infringement of the LICENSED PATENTS
in the LICENSED FIELD by granting the infringing party a sublicense under the
provisions of Paragraph 12 of this Agreement.
4
14. Improvements: Inventions or IMPROVEMENTS conceived or reduced to practice
solely by a party during the term of and in connection with this Agreement shall
be owned exclusively by such party.
15. Patent Validity: Nothing in this Agreement precludes Lactoferrin from
contesting the validity of an LICENSED PATENT.
16. Entire Agreement: This Agreement constitutes the entire understanding and
agreement between the Parties, reflects all the agreements, understandings,
representations, conditions and warranties by and between the parties, and any
prior understanding or representation of any kind preceding the Effective Date
shall not be binding upon either party unless expressly stated herein in writing
or clearly and expressly incorporated by reference herein in writing. The
execution of this Agreement has not been induced by, nor do any of the parties
hereto rely upon or regard as material, any representations or promises whatever
except to the extent expressly stated herein in writing or clearly and expressly
incorporated by reference herein in writing. No party shall be liable for any
representation made or omitted unless it is expressly set forth in this
Agreement.
17. Warranty of Authority: Any such execution is a representation and warranty
to the other party that the party so signing has full authority in all requisite
capacities to do so. In the event of any loss or damage suffered by a party due
to this representation or warranty being untrue, whether innocent or otherwise,
then the party causing the harm shall indemnify the other party in respect of
all loss or damage, and reasonable costs and expenses connected therewith.
18. Inurement: This Agreement shall be binding upon and inure to the benefit of
the Parties and their respective heirs, representatives, successors and assigns.
19. Counterparts and Fax Copies: This Agreement may be executed in counterparts
and may be delivered by fax copies thereof and when the whole is so executed and
delivered it shall
5
constitute a valid and binding agreement among the parties so executing and
delivering the agreement effective as of the Effective Date. Fax Signatures
shall be deemed to be accepted as original.
20. Severability: If one or more or any part of the individual provisions in
this Agreement should be deemed contrary to law, then such provisions or parts
thereof shall be null and void and shall be deemed separable from the remaining
provisions or parts thereof and shall in no way affect the validity or
enforceability of any remaining provision of this Agreement.
21. Law and Jurisdiction: This Agreement shall be subject to the Laws of the
State of Minnesota. All parties shall be subject to jurisdiction in the States
of Texas and Minnesota.
IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed
and delivered on the date first above written.
BIOPOLYMER ENGINEERING, INC.
Date: July 22, 2000 Per: /s/ DANIEL K. CONNERS
------------------- ---------------------------
Daniel K. Conners
LACTOFERRIN PRODUCTS COMPANY
Date: 7/22/2000 Per: /s/ MARCUS GOHLKE, PRES
------------------- ---------------------------
Marcus Gohlke, President
6
SUBLICENSE AGREEMENT
(ATTACHMENT A)
THIS SUBLICENSE AGREEMENT is made and is effective as of _____________________
(date) by and between Lactoferrin Products Company and its parent, related or
affiliated corporations (together called "Sublicensor") of 12302 Astoria
Boulevard, Houston, TX 77089 and ______________________________________________
(name) having a place of business at __________________________________________
(address) (herein called "Sublicensee").
WHEREAS, Sublicensor is the exclusive licensee of Biopolymer Engineering
Inc. (herein called "BEI") of nutritional and dietary supplements incorporating
beta 1,3/1,6 glucan, and/or beta 1,3 glucan, and/or derivative(s) of these
glucans and which use an oral cavity delivery system (for example, losenges) or
formulation, excluding capsules, tablets or any system which delivers outside
the oral cavity.
NOW WITNESS THEREFORE that in consideration of the premises and the
provisions, stipulations and matters herein set out, the Parties hereto hereby
agree as follows:
1. Definitions: When used in this Agreement, the terms set forth below shall
have the meanings indicated:
EFFECTIVE DATE of this Agreement shall be the date first above
indicated.
IMPROVEMENTS shall mean improvements to the formulation or method of
making the LICENSED PRODUCT within the LICENSED FIELD.
LICENSED FIELD shall mean the field of dietary and nutritional
supplements incorporating beta 1,3/1,6 glucan, and/or beta 1,3 glucan, and/or
derivative(s) of these glucans
7
and using an oral cavity delivery system (for example, losenges) or formulation,
excluding capsules, tablets or any system which delivers outside the oral
cavity.
LICENSED PRODUCT means any and all products that employ, are produced
by the practice of, or used in accordance with inventions claimed in the
LICENSED PATENTS or other patents related to the LICENSED FIELD.
LICENSED PATENTS shall means United States Patents issued numbers:
5,576,015; 5,519,009; 5,397,773; 5,705,184; and 5,702,719 and patents which
relate to inventions in or applicable to the LICENSED PRODUCT and which are
owned or controlled by BEI during the term of this Agreement, or in respect to
which BEI has or may acquire during the term of this Agreement the right to
grant licenses of the scope to be granted in this Agreement.
TRADEMARK shall mean the term "Beta Right" and any rights established
by United States trademark application Serial Number 75/912,109.
2. Technology Sublicense: Sublicensor grants to Sublicensee a nonexclusive
license to make, have made, use, sell, offer for sale, and import the LICENSED
PRODUCT embodying, made, or used in accordance with the LICENSED PATENTS for use
in the LICENSED FIELD.
3. Technology Use: For all products which Sublicensee shall make, have made,
use, sell, offer for sale, and import under the license of Paragraph 2, the
products shall contain an effective amount of beta 1,3/1,6 glucan, and/or beta
1,3 glucan, and/or derivative(s) of these glucans, wherein an "effective amount"
is defined as a recommended dose of 40 mg/day.
4. Trademark License: Sublicensor grants to Sublicensee a nonexclusive license
to use the TRADEMARK in association with LICENSED PRODUCT in the LICENSED FIELD.
5. Trademark Use and Control: Sublicensee shall use the TRADEMARK on all
packaging and labels associated with products containing LICENSED PRODUCT.
8
Approximately once every six months and at Sublicensor's written request,
Sublicensee shall provide a sample of LICENSED PRODUCT to Sublicensor.
6. Purchase: Sublicensee shall purchase beta 1,3/1,6 glucan and/or beta 1,3
glucan exclusively from BEI: Sublicensor.
7. Consideration: Good and valuable consideration is hereby given in support
of this agreement, receipt of which is hereby acknowledged.
8. Sub-sublicense: Sublicensee shall have no right to sub-sublicense rights
granted under this Agreement.
9. Improvements: Inventions or IMPROVEMENTS conceived or reduced to practice
by either party during the time of and in connection with this Agreement shall
be owned exclusively by Sublicensor.
10. Entire Agreement: This Agreement constitutes the entire understanding and
agreement between the Parties, represents all the agreements, understandings,
representations, conditions and warranties by and between the parties, and any
prior understanding or representation of any kind preceding the Effective Date
shall not be binding upon either party unless expressly stated herein in writing
or clearly and expressly incorporated by reference herein in writing. The
execution of this Agreement has not been induced by, nor do any of the parties
hereto rely upon or regard as material, any representations or promises whatever
except to the extent expressly stated herein in writing or clearly and expressly
incorporated by reference herein in writing. No party shall be liable for any
representation made or omitted unless it is expressly set forth in this
Agreement.
11. Warranty of Authority: Any such execution is a representation and warranty
to the other party that the party signing has full authority in all requisite
capacities to do so. In the event of any loss or damage suffered by a party due
to this representation or warranty being
9
untrue, whether innocent or otherwise, then the party causing the harm shall
indemnify the other party in respect of all loss or damage, and reasonable costs
and expenses connected therewith.
12. Inurement: This Agreement shall be binding upon and inure to the benefit of
the Parties and their respective heirs, representatives, successors and assigns.
13. Counterparts and Fax Copies: This Agreement may be executed in counterparts
and may be delivered by fax copies thereof and when the whole is so executed and
delivered it shall constitute a valid and binding agreement among the parties so
executing and delivering the agreement effective as of the Effective Date. Fax
Signatures shall be deemed to be accepted as original.
14. Severability: If one or more or any part of the individual provisions in
this Agreement should be deemed contrary to law, then such provisions or parts
thereof shall be null and void and shall be deemed separable from the remaining
provisions or parts thereof and shall in no way affect the validity or
enforceability of any remaining provision of this Agreement.
15. Law and Jurisdiction: This Agreement shall be subject to the Laws of the
State of Minnesota. All parties shall be subject to jurisdiction in the States
of Texas and Minnesota.
IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed
and delivered on the date first above written.
SUBLICENSEE
Date: Per:
------------------- ------------------------------
Title:
-----------------------------
SUBLICENSOR
Date: Per:
------------------- ------------------------------
Title:
-----------------------------
10
EXHIBIT C - ACKNOWLEDGMENT BY BIOPOLYMER ENGINEERING, INC.
Acknowledgement by Biopolymer Engineering, Inc.
1. Biopolymer Engineering, Inc. is the holder of all rights under United
States Patent Numbers: 5,519,009; 5,397,773; 5,576,015; 5,705,184; and
5,702,719.
2. Biopolymer Engineering, Inc. confirms it has licensed some of its rights
under United States Patent Numbers: 5,519,009; 5,397,773; 5,576,015; 5,705,184;
and 5,702,719 to Lactoferrin Products Company according to the terms of a
license agreement effective the 22nd day of July, 2000 ("BIOPOLYMER-LACTOFERRIN
AGREEMENT"). A true and correct copy of the BIOPOLYMER-LACTOFERRIN AGREEMENT is
attached hereto as ATTACHMENT C1.
3. Biopolymer Engineering, Inc. consents and agrees to a license of rights
under United States Patent Numbers: 5,519,009; 5,397,773; 5,576,015; 5,705,184;
and 5,702,719 according to the terms of an agreement between Lactoferrin
Products Company, Marcus B. Gohlke and Mannatech Incorporated ("LACTOFERRIN-
MANNATECH AGREEMENT"). A redacted copy of the LACTOFERRIN-MANNATECH AGREEMENT is
attached hereto as ATTACHMENT C2.
4. Biopolymer Engineering, Inc. represents that the BIOPOLYMER-LACTOFERRIN
AGREEMENT is in full force and effect, that there is no default existing or
event known, which upon due notice without cure, would cause a default in said
BIOPOLYMER-LACTOFERRIN AGREEMENT ("Event of Default"). Biopolymer Engineering,
Inc. further agrees to notify Mannatech should a default or Event of Default
occur under the BIOPOLYMER-LACTOFERRIN AGREEMENT with notification sent by
courier, mail, electronic mail or electronic transmission (facsimile) confirmed
by certified mail to Mannatech at the address set forth below:
Mannatech Incorporated
600 S. Royal Lane, Suite 200
Coppell, Texas 75019
Attn: Terry Persinger with confirmation to Deanne Varner
Phone: 972 471 7387
Email: tpersinger@mail.mannatech-inc.com
5. Biopolymer Engineering, Inc. is aware that Mannatech is relying upon the
foregoing statements and undertaking set forth above, in entering into the
LACTOFERRIN-MANNATECH AGREEMENT.
- ------------------------------ ------------------------------
Daniel K. Conners Date
President
Biopolymer Engineering, Inc.
EXHIBIT D - ASSIGNMENT TO LACTOFERRIN
[LETTERHEAD OF DEPARTMENT OF COMMERCE]
FEBRUARY 15, 2000
PTAS [BAR CODE]
FROHWITTER
R. WILLIAM BEARD, JR. [RECEIVED DATE STAMP]
THREE RIVERWAY, SUITE 500
HOUSTON, TEXAS 77056
UNITED STATES PATENT AND TRADEMARK OFFICE
NOTICE OF RECORDATION OF ASSIGNMENT DOCUMENT
THE ENCLOSED DOCUMENT HAS BEEN RECORDED BY THE ASSIGNMENT DIVISION OF THE U.S.
PATENT AND TRADEMARK OFFICE. A COMPLETE MICROFILM COPY IS AVAILABLE AT THE
ASSIGNMENT SEARCH ROOM ON THE REEL AND FRAME NUMBER REFERENCED BELOW.
PLEASE REVIEW ALL INFORMATION CONTAINED ON THIS NOTICE. THE INFORMATION
CONTAINED ON THIS RECORDATION NOTICE REFLECTS THE DATA PRESENT IN THE PATENT AND
TRADEMARK ASSIGNMENT SYSTEM. IF YOU SHOULD FIND ANY ERRORS OR HAVE QUESTIONS
CONCERNING THIS NOTICE, YOU MAY CONTACT THE EMPLOYEE WHOSE NAME APPEARS ON THIS
NOTICE AT 703-308-9723. PLEASE SEND REQUEST FOR CORRECTION TO: U.S. PATENT
AND TRADEMARK OFFICE, ASSIGNMENT DIVISION, BOX ASSIGNMENTS, CG-4, 1213 JEFFERSON
DAVIS HWY, SUITE 320, WASHINGTON, D.C. 20231.
RECORDATION DATE: 11/12/1999 REEL/FRAME: 010379/0796
NUMBER OF PAGES: 3
BRIEF: ASSIGNMENT OF ASSIGNOR'S INTEREST (SEE DOCUMENT FOR DETAILS).
ASSIGNOR:
GOHLKE, MARCUS B. DOC DATE: 10/25/1999
ASSIGNOR:
COCKRUM, RICHARD H. DOC DATE: 10/27/1999
ASSIGNEE:
LACTOFERRIN PRODUCTS COMPANY
12302 ASTORIA BOULEVARD
HOUSTON, TEXAS 77089-6403
SERIAL NUMBER: 09370654 FILING DATE: 08/06/1999
PATENT NUMBER: ISSUE DATE:
SONYA JOHNSON, EXAMINER
ASSIGNMENT DIVISION
OFFICE OF PUBLIC RECORDS
ORIGINAL ASSIGNMENT
For valuable consideration, I (we) the below signed inventor(s) of record,
hereby assign to
LactoFerrin Products Company
having a place of business at:
12302 Astoria Boulevard
Houston, Texas 77089-6403
and its successors and assigns (collectively hereinafter called "the Assignee"),
the entire right, title and interest throughout the world in the inventions and
improvements which are the subject of United States Provisional Application
Serial Number 06/096,697, filed August 13, 1998, Atty Docket No. L71299US, and
which are the subject of an application to be filed under 37 CFR (S) 1.53(b),
Atty Docket No. L71803US, both applications entitled:
"Dietary Supplement Combining Colostrum and Lactoferrin in a Mucosal
Delivery Format"
this assignment including said application, any and all United States and
foreign patents, utility models, design registrations, inventor's certificates
and other similar rights granted for any of said inventions or improvements, and
the right to claim priority based on the filing date of said application under
the International Convention for the Protection of Industrial Property, the
Patent Cooperation Treaty, the European Patent Convention, and all other
treaties of like purposes; and I authorize the Assignee to apply in all
countries in my name, or in its own name, for patents, utility models, design
registrations and like rights of exclusion and for inventors' certificates for
said inventions and improvements; and I agree for myself and my heirs, legal
representatives and assigns, without further compensation to perform such lawful
acts and to sign such further applications, assignments, Preliminary Statements
and other lawful documents as the Assignee may reasonably request to effectuate
fully this assignment.
IN WITNESS WHEREOF, I hereby set my hand, date of signature and place of
signature as indicated below.
Full Name of Sole or First Joint
(if other names listed below) Inventor: Marcus B. Gohlke
-------------------------------
Residence: 12302 Astoria Boulevard, Houston, Texas 77089
--------------------------------------------------------------
Citizenship: United States of America
--------------------------------------------------------------
Post Office Address: 12302 Astoria Boulevard, Houston, Texas 77089
-----------------------------------------------------
/s/ MARCUS B. GOHLKE 10/25/99 HOUSTON, USA
- ----------------------------------- ----------------- ------------------
Signature of Sole or First Inventor Date of Signature Place of Signature
(City, Country)
Full Name of Second Joint Inventor: Richard H. Cockrum
--------------------------------------------
Residence: Intersection Highway 141 and 169, Perry, Iowa 50220
--------------------------------------------------------------------
Citizenship: United States of America
--------------------------------------------------------------------
Post Office Address: Intersection Highway 141 and 169, Perry, Iowa 50220
----------------------------------------------------------
/s/ RICHARD H. COCKRUM 10-27-99 PERRY IOWA USA
- ------------------------------------- ----------------- ------------------
Signature of Second-Inventor Date of Signature Place of Signature
(City, Country)
Page 1 of Original Assignment
Term Sheet
Parties: Lactoferrin Products Company, Marcus Gohlke and
Mannatech/TM/, Incorporated
Type: Licensing & Fulfillment Agreement
Term: Three Years ("Initial Term") beginning on the date of
-----------
effective date with three year renewal terms:
(a) First Renewal Term
------------------
Continuing for three (3) years, concluding at the
end of the sixth (6) year;
(b) Secondary Renewal Term
----------------------
Continuing for three (3) years, concluding at the
end of the ninth (9) year; and
(c) Third Renewal Term
------------------
Continuing for three (3) years, concluding at the
end of the twelfth (12) year.
Termination: Lactoferrin may immediately terminate (with notice
-----------
and 60 days opportunity to cure):
(a) In the event Mannatech alters the Licensed Product
beyond that previously approved by Lactoferrin;
(b) If Mannatech purchases or obtains Raw Materials
from a source without Lactoferrin's prior consent;
(c) If Mannatech dissolves, becomes bankrupt or if
Lactoferrin is sued for patent infringement.
Mannatech may immediately terminate (with notice and
---------
60 days opportunity to cure):
(a) If Lactoferrin supplies Raw Materials from any
source not previously agreed to between the
parties; and/or
(b) If Mannatech is advised by counsel that Mannatech's
activities constitute patent infringement
Termination by law in the event it becomes illegal to
------------------
market dietary supplements containing beta glucan,
colostrum or lactoferrin.
Licensed Product: Mannatech will receive a worldwide license to market a
solid dietary supplement with a formulation containing:
Prime Colostrum, Beta 1,3/1,6 Glucan, Lactoferrin and
modified citrus pectin.
Exclusivity: Worldwide rights to the Licensed Product. Lactoferrin
---------
Retains rights to its products containing any of the
following combinations colostrum, lactoferrin, modified
citrus pectin and beta glucan, but not the combination
of the above and beta 1,3/1,6 Glucan.
1
Asia Exception - Lactoferrin can continue to sell a
--------------
product containing a lactoferrin and colostrum mixture
under a pre-existing contract. Lactoferrin will cease
sales upon one (1) year notice by Mannatech of its
intent to enter market with Licensed Product or (2)
Mannatech's actual entry into market.
Japan - in no event will Lactoferrin market products
-----
for sale or eventual sale in Japan.
Improvements: Any improvements made to the Licensed Product will be
owned by Mannatech.
Each party may file for patents on its own behalf and
bear all costs/fees associated with filing.
Compensation:
(1) Raw Materials:
-------------
Lactoferrin will deliver Colostrum powder (bulk) to
---------
Mannatech at a cost not to exceed $120 per KG for
the Initial Term.
Glucan 1,3/1,6 powder (bulk) will be delivered to
--------------
Mannatech at a cost not to exceed $500 per KG for
the Initial Term.
All prices may be negotiated lower depending upon
the amount purchased by Mannatech.
(2) Product Royalty:
---------------
Contract Year 1: $144,000 annually (minimum)
Contract Year 2: Greater of: $8,000/month or
110% of the average monthly
number of units shipped in Year
1/month.
Contract Year 3: 110% of the average number of
Royalty Units shipped in Year 2.
Renewal Terms: Negotiable, but not less than
$5,000 per month.
In the event the monthly amount exceeds the
minimum, then Mannatech will pay a royalty on a per
Royalty Unit basis. The cost will be adjusted down
as follows:
1-540,000 Units = $1.00 per Royalty Unit
540,001 - 1,540,000 = .90 per Royalty Unit
Over 1,540,000 = .80 per Royalty Unit
2
(3) Advertising Royalty:
-------------------
(a) Written Materials:
Developed with Lactoferrin assistance:
(negotiable)
Developed by or for Mannatech by 3/rd/
party: No Royalty paid.
(b) Audio/Video:
Developed with Lactoferrin assistance:
5% of sales price.
(c) Lactoferrin agrees to sell the book entitled,
Immune System Control to Mannatech for sale to
---------------------
its Associates at a cost of $2.95 plus s/h. No
Royalties will be paid to Lactoferrin upon sale
of the book.
(4) Travel Costs:
------------
Mannatech will reimburse Gohlke in the event his
presence is requested at a location more than fifty
(50) miles from his residence. Inclusive of travel,
meals, and lodging expenses.
Assurances: Lactoferrin and/or Gohlke represents and warrants that:
(1) The Licensed Product sold to Mannatech is an
exclusive formulation, not previously produced,
marketed or sold;
(2) There are no similar products derived from the
formulation of the Product;
(3) That it and/or its partners/business associates
have patents pending for the Licensed Product and
he/they reasonably believe such patents will be
granted;
(4) Lactoferrin is a corporation duly organized and in
good standing under the laws of its state of
incorporation;
(5) All necessary business governance issues have be
authorized to enter the agreement;
(6) No other consent is required to enter the
agreement;
(7) Entering this Agreement will not cause Lactoferrin
to breach any other agreement of which it is a
party pertaining to the subject matter of this
agreement;
(8) All taxes are current;
(9) Lactoferrin is solvent; and
(10) Relationship between Lactoferrin and its suppliers
and customers is generally good.
3
Specific Mannatech
Obligations: (1) Will label product packaging in accordance with
(S)(S) 3.4., 3.5 and 3.6, pertaining to trademarks,
patent notices and packaging, respectively;
(2) Mannatech will use its best efforts to market the
Licensed Product;
(3) Mannatech cannot deviate from the ingredient ranges
set forth in the agreement;
(4) Mannatech will purchase the raw materials from
suppliers as specified in the agreement.
Standard
Provisions: (1) Confidentiality;
(2) Trade Marks, Intellectual Property and Trade
Secrets belong to the respective parties;
(3) Cooperation with patent filing; and
(4) Indemnification;
(5) Choice of Law: Texas (Harris County)
4